Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$1.30 USD
+0.06 (4.84%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Brokerage Reports
Hepion Pharmaceuticals, Inc. [HEPA]
Reports for Purchase
Showing records 41 - 52 ( 52 total )
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 12 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CRV431 Shines Brightest in Human Liver Slice Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Part 3: "Must-See" Companies at JPM (Mkt. Cap. <$100M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Make Way for the New Kid on the NASH Block; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y